HIV seroincidence and risk factors among patients repeatedly tested for HIV attending sexually transmitted disease clinics in the United States, 1991 to 1996

被引:57
作者
Weinstock, H [1 ]
Sweeney, S [1 ]
Satten, GA [1 ]
Gwinn, M [1 ]
机构
[1] Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA
关键词
HIV-1; incidence; sexually transmitted diseases; homosexuality;
D O I
10.1097/00042560-199812150-00010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To assess the incidence of HIV infection and risk factors associated with HIV seroconversion among patients attending clinics for sexually transmitted diseases (STD), medical record reviews were conducted in 12 clinics in 7 U.S. cities. The records of all patients who initially tested negative for HIV from 1991 through 1996 and who received at least one additional HIV rest during the study period were reviewed. In each of 7 cities, 5 to 112 patients seroconverted. Of the 286 seroconverters identified in total, 53% (152 of 286) were heterosexual men and 28% (81 of 286) were women. HIV incidence rates among men who have sex with men (MSM) ranged by city from 0.81 to 7.0 new infections/100 person-years. Rates among heterosexual men and women ranged from 0.018 to 1.2 infections/100 person-years. Multivariate analyses showed that drugs use was associated with HIV seroconversion only among heterosexuals. Most new HIV infections in these clinics are being transmitted heterosexually and are associated with drug use. Nevertheless, MSM, particularly young MSM, are at greatest risk for HIV in this population: 1 of 47 seroconvert/year. The effective use of targeted prevention efforts depends upon the continued ability to monitor the incidence of HIV infection.
引用
收藏
页码:506 / 512
页数:7
相关论文
共 35 条
[1]   HIV-INFECTION IN INTRAVENOUS-DRUG-USERS ENTERING DRUG-TREATMENT, UNITED-STATES, 1988 TO 1989 [J].
ALLEN, DM ;
ONORATO, IM ;
GREEN, TA ;
BLEDSOE, G ;
COLLIE, D ;
CONNELL, T ;
DEPPE, D ;
EDGAR, G ;
EFIRD, J ;
FORRESTER, W ;
MEEK, B ;
RUBERTI, D ;
SANDERS, R ;
SLOANE, S .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1992, 82 (04) :541-546
[2]   HIGH HIV-1 INCIDENCE IN YOUNG-WOMEN MASKED BY STABLE OVERALL SEROPREVALENCE AMONG CHILDBEARING WOMEN IN KINSHASA, ZAIRE - ESTIMATING INCIDENCE FROM SERIAL SEROPREVALENCE DATA [J].
BATTER, V ;
MATELA, B ;
NSUAMI, M ;
MANZILA, T ;
KAMENGA, M ;
BEHETS, F ;
RYDER, RW ;
HEYWARD, WL ;
KARON, JM ;
STLOUIS, ME .
AIDS, 1994, 8 (06) :811-817
[3]   Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: Risk behavior, seroincidence, and willingness to participate [J].
Buchbinder, SP ;
Douglas, JM ;
McKirnan, DJ ;
Judson, FN ;
Katz, MH ;
MacQueen, KM .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (05) :954-961
[4]   HUMAN IMMUNODEFICIENCY VIRUS (HIV) SEROPREVALENCE IN PERSONS ATTENDING STD CLINICS IN THE UNITED-STATES, 1985-1987 [J].
CANNON, RO ;
SCHMID, GP ;
MOORE, PS ;
PAPPAIOANOU, M .
SEXUALLY TRANSMITTED DISEASES, 1989, 16 (04) :184-189
[5]   Antiretroviral therapy for HIV infection in 1997 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (24) :1962-1969
[6]  
*CDCP, 1997, HIV AIDS SURV REP, V9, P31
[7]  
*CDCP, 1993, NAT HIV SER SUMM RES
[8]  
Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P155
[9]  
Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P165
[10]  
Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P81